Cover Image
市場調查報告書

Protalix BioTherapeutics, Inc.:產品平台分析

Protalix BioTherapeutics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 226228
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
Protalix BioTherapeutics, Inc.:產品平台分析 Protalix BioTherapeutics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年11月18日 內容資訊: 英文 29 Pages
簡介

Protalix BioTherapeutics, Inc.ha是開發,製造治療用重組蛋白的生物醫藥品企業。

本報告提供Protalix BioTherapeutics, Inc.的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,彙整最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Protalix BioTherapeutics, Inc.的基本資料

Protalix BioTherapeutics, Inc.概要

  • 主要資訊
  • 企業資料

Protalix BioTherapeutics, Inc.:R&D概要

  • 主要的治療範圍

Protalix BioTherapeutics, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Protalix BioTherapeutics, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Protalix BioTherapeutics, Inc.:藥物簡介

  • taliglucerase alfa
  • PRX-112
  • PRX-102
  • etanercept biosimilar
  • PRX-105
  • PRX-107
  • PRX-110
  • PRX-111
  • PRX-113

Protalix BioTherapeutics, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Protalix BioTherapeutics, Inc.:最近的開發平台趨勢

Protalix BioTherapeutics, Inc.:暫停中的計劃

Protalix BioTherapeutics, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • PRX-111
    • taliglucerase alfa

Protalix BioTherapeutics, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07705CDB

Summary

Global Markets Direct's, 'Protalix BioTherapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Protalix BioTherapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Protalix BioTherapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Protalix BioTherapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Protalix BioTherapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Protalix BioTherapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Protalix BioTherapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Protalix BioTherapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Protalix BioTherapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Protalix BioTherapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Protalix BioTherapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Protalix BioTherapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Protalix BioTherapeutics, Inc. Snapshot
    • Protalix BioTherapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Protalix BioTherapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Protalix BioTherapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Protalix BioTherapeutics, Inc. - Pipeline Products Glance
    • Protalix BioTherapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Protalix BioTherapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Protalix BioTherapeutics, Inc. - Drug Profiles
    • PRX-112
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PRX-102
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PRX-110
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Protalix BioTherapeutics, Inc. - Pipeline Analysis
    • Protalix BioTherapeutics, Inc. - Pipeline Products by Target
    • Protalix BioTherapeutics, Inc. - Pipeline Products by Route of Administration
    • Protalix BioTherapeutics, Inc. - Pipeline Products by Molecule Type
    • Protalix BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Protalix BioTherapeutics, Inc. - Recent Pipeline Updates
  • Protalix BioTherapeutics, Inc. - Dormant Projects
  • Protalix BioTherapeutics, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • taliglucerase alfa
  • Protalix BioTherapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Protalix BioTherapeutics, Inc., Key Information
  • Protalix BioTherapeutics, Inc., Key Facts
  • Protalix BioTherapeutics, Inc. - Pipeline by Indication, 2015
  • Protalix BioTherapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Protalix BioTherapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Protalix BioTherapeutics, Inc. - Phase II, 2015
  • Protalix BioTherapeutics, Inc. - Phase I, 2015
  • Protalix BioTherapeutics, Inc. - Preclinical, 2015
  • Protalix BioTherapeutics, Inc. - Pipeline by Target, 2015
  • Protalix BioTherapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Protalix BioTherapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Protalix BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Protalix BioTherapeutics, Inc. - Recent Pipeline Updates, 2015
  • Protalix BioTherapeutics, Inc. - Dormant Developmental Projects,2015
  • Protalix BioTherapeutics, Inc. - Discontinued Pipeline Products, 2015

List of Figures

  • Protalix BioTherapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Protalix BioTherapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Protalix BioTherapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Protalix BioTherapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Protalix BioTherapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Protalix BioTherapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Protalix BioTherapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top